WallStSmart

Pasithea Therapeutics Corp (KTTA)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Revolution Medicines Inc generates 52% more annual revenue ($742,000 vs $486,560). RVMD leads profitability with a 0.0% profit margin vs 0.0%. KTTA earns a higher WallStSmart Score of 38/100 (F).

KTTA

Hold

38

out of 100

Grade: F

Growth: 6.3Profit: 3.0Value: 5.0Quality: 7.3
Piotroski: 3/9Altman Z: 4.85

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KTTA3 strengths · Avg: 10.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
1498.0%10/10

Revenue surging 1498.0% year-over-year

Altman Z-ScoreHealth
4.8510/10

Safe zone — low bankruptcy risk

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

KTTA4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$19.55M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : KTTA

The strongest argument for KTTA centers on Price/Book, Revenue Growth, Altman Z-Score. Revenue growth of 1498.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : KTTA

The primary concerns for KTTA are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

KTTA profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

KTTA is growing revenue faster at 1498.0% — sustainability is the question.

KTTA generates stronger free cash flow (-5M), providing more financial flexibility.

Bottom Line

KTTA scores higher overall (38/100 vs 24/100) and 1498.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Pasithea Therapeutics Corp

HEALTHCARE · BIOTECHNOLOGY · USA

Pasithea Therapeutics Corp. The company is headquartered in Miami Beach, Florida.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?